Abstract:Chronic active multiple sclerosis lesions, characterized by a hyperintense rim of iron-enriched, activated microglia and macrophages, have been linked to greater tissue damage. Post-mortem studies have determined that chronic active lesions are primarily related to the later stages of multiple sclerosis; however, the occurrence of these lesions, and their relationship to earlier disease stages may be greatly underestimated. Detection of chronic active lesions across the patient spectrum of multiple sclerosis requires a validated imaging tool to accurately identify lesions with persistent inflammation. Quantitative susceptibility mapping provides efficient in vivo quantification of susceptibility changes related to iron deposition and the potential to identify lesions harbouring iron-laden inflammatory cells. The PET tracer 11C-PK11195 targets the translocator protein expressed by activated microglia and infiltrating macrophages. Accordingly, this study aimed to validate that lesions with a hyperintense rim on quantitative susceptibility mapping from both relapsing and progressive patients demonstrate a higher level of innate immune activation as measured on 11C-PK11195 PET. Thirty patients were enrolled in this study, 24 patients had relapsing remitting multiple sclerosis, six had progressive multiple sclerosis, and all patients had concomitant MRI with a gradient echo sequence and PET with 11C-PK11195. A total of 406 chronic lesions were detected, and 43 chronic lesions with a hyperintense rim on quantitative susceptibility mapping were identified as rim+ lesions. Susceptibility (relative to CSF) was higher in rim+ (2.42 ± 17.45 ppb) compared to rim- lesions (-14.6 ± 19.3 ppb, P < 0.0001). Among rim+ lesions, susceptibility within the rim (20.04 ± 14.28 ppb) was significantly higher compared to the core (-5.49 ± 14.44 ppb, P < 0.0001), consistent with the presence of iron. In a mixed-effects model, 11C-PK11195 uptake, representing activated microglia/macrophages, was higher in rim+ lesions compared to rim- lesions (P = 0.015). Validating our in vivo imaging results, multiple sclerosis brain slabs were imaged with quantitative susceptibility mapping and processed for immunohistochemistry. These results showed a positive translocator protein signal throughout the expansive hyperintense border of rim+ lesions, which co-localized with iron containing CD68+ microglia and macrophages. In conclusion, this study provides evidence that suggests that a hyperintense rim on quantitative susceptibility measure within a chronic lesion is a correlate for persistent inflammatory activity and that these lesions can be identified in the relapsing patients. Utilizing quantitative susceptibility measure to differentiate chronic multiple sclerosis lesion subtypes, especially chronic active lesions, would provide a method to assess the impact of these lesions on disease progression.

TSPO-Detectable Chronic Active Lesions Predict Disease Progression in Multiple Sclerosis

Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis

Early prognosticators of later TSPO-PET-measurable microglial activation in multiple sclerosis

TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy

Characterization of cortico-meningeal translocator protein expression in multiple sclerosis

Neuroinflammatory component of gray matter pathology in multiple sclerosis

Long-term clinical, imaging and cognitive outcomes association with MS immunopathology

Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals

Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.

P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study

Quantifying chronic lesion expansion in multiple sclerosis: Exploring imaging markers for longitudinal assessment

Predicting PET-derived myelin content from multisequence MRI for individual longitudinal analysis in multiple sclerosis

Integration of magnetic resonance imaging and protein and metabolite CSF measurements to enable early diagnosis of secondary progressive multiple sclerosis

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting

The evolving contribution of MRI measures towards the prediction of secondary progressive multiple sclerosis

Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis

Gray Matter Microglial Activation in Relapsing Vs Progressive MS: A [F-18]PBR06-PET Study.

Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration

Microstructural characterization of multiple sclerosis lesion phenotypes using multiparametric longitudinal analysis

A Radiomic "Warning Sign" of Progression on Brain MRI in Individuals with MS

The T1-dark-rim: A novel imaging sign for detecting smoldering inflammation in multiple sclerosis